Processa Pharmaceuticals (PCSA)CEO bought ~$5.5K

~$5.5K

Approx. value · 2,465 sh @ $2.22

12K

Holds after · shares reported

Traded

Jun 15, 2026

Filed

Jun 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 31, 2026Insider · 9 insiders in a week, a first since 2020CEO purchased ~$5.4K of PCSA shares in the open market
2. Apr 15, 2026Insider · 6 peopleInsiders: 6 purchases (~$30K)
3. Apr 30, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.”
4. Apr 30, 2026Insider · 6 peopleInsiders: 6 purchases (~$30K)
5. May 15, 2026Insider · 5 peopleInsiders: 5 purchases (~$25K)
6. May 29, 2026Insider · 5 peopleInsiders: 5 purchases (~$25K)
7. Jun 15, 2026 · this disclosureInsider · 5 insiders in a week, 3rd time since 2020CEO purchased ~$5.5K of PCSA shares in the open market

What came next

1. Jun 15, 2026Insider · 4 peopleInsiders: 4 purchases (~$19K)
2. Jun 30, 2026Insider · 4 peopleInsiders: 4 purchases (~$20K)
3. Jul 1, 2026Insider · 5 insiders in a week, 4th time since 2020CEO purchased ~$5.9K of PCSA shares in the open market
4. Jul 23, 2026Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and changed a top executive or board member (and 5 more items)“Appointment of Directors In accordance with the Merger Agreement, on July 28, 2026, effective immediately after the First Effective Time, Sheila Gujrathi was appointed to the Board as a director.”
5. Jul 30, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On July 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, shareholders of the Company approved an amendment to Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan (“Incentive Plan”) to increase the number of shares available for issuance under the plan by 200,000 shares.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Processa Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Processa Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PCSA page.

Other recent filings by George K Ng, Chief Executive Officer

• SEC Form 4 at Processa Pharmaceuticals (PCSA)Jul 2, 2026
• SEC Form 4 at Processa Pharmaceuticals (PCSA)Jun 2, 2026
• SEC Form 4 at Processa Pharmaceuticals (PCSA)May 20, 2026
• SEC Form 4 at Processa Pharmaceuticals (PCSA)May 20, 2026
• SEC Form 4 at Processa Pharmaceuticals (PCSA)May 2, 2026

The full history of George K Ng, Chief Executive Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Processa Pharmaceuticals

• SEC Form 4Jul 2, 2026
• SEC Form 4Jul 2, 2026
• SEC Form 4Jul 2, 2026
• SEC Form 4Jul 2, 2026
• SEC Form 4Jul 2, 2026
• SEC Form 4Jun 17, 2026

Everything OQRO holds on this company is on its PCSA page.